This 5-year renewal application is directed at using 14beta-(bromoacetamido)-7,8-dihydromorphine (H2BAM) to affinity label and purify the mu opioid receptor. In the absence of a disulfide bond reducing reagent, this affinity ligand bound reversibly to the mu opioid binding site in rat brain membranes. However, after reduction of a disulfide bond at the mu opioid binding site, H2BAM bound irreversibly to this binding site, as determined by the inhibition of opioid binding to the mu site, but not to the delta or kappa site. Protection experiments demonstrated that only opioids that bind to the mu opioid binding site were able to block the alkylation of this site. [3H]H2BAM was synthesized to a high specific activity. The affinity and specificity of [3H]H2BAM to bind reversibly and irreversibly to the mu opioid binding site in rat and bovine brain membranes will be determined by radioreceptor binding assays in the presence and absence of the disulfide bond reducing reagent dithiothreitol. Experimental conditions will be optimized for the specific alkylation of the mu opioid binding site with [3H]H2BAM. The molecular weight of protein(s) specifically labeled with [3H]H2BAM will be determined by separating [3H]H2BAM-labeled membranes on polyacrylamide gels under denaturing and reducing conditions, followed by fluorography. Specificity studies will determine which opioids can block the irreversible labeling of specific protein(s). The possibility of multiple mu opioid binding sites will be examined. Cell lines, specific brain regions, and other tissues will be tested to further characterize the specificity of [3H]H2BAM alkylation of membranes. These studies will result in a profile of the affinity labeling of the mu opioid binding site. Proteins, specifically labeled with [3H]H2BAM, will be purified from bovine striatal membranes under denaturing conditions, including affinity chromatography, high pressure liquid chromatography (HPLC), using ion exchange and molecular sieve columns, and gel electrophoresis. Peptide fragments from the purified [3H]H2BAM-labeled protein will be generated by enzyme or chemical digestion. Peptides will purified by reverse-phase HPLC, and partial amino acid sequences of the peptides will be determined. Based on the amino acid sequences, oligonucleotide probes will be synthesized, and used to screen cDNA libraries, in order to ultimately clone the mu opioid receptor.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA003742-09
Application #
2116806
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1984-07-01
Project End
1994-07-31
Budget Start
1992-08-01
Budget End
1993-07-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Rochester
Department
Pharmacology
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Rusovici, Daniela E; Negus, S Stevens; Mello, Nancy K et al. (2004) Kappa-opioid receptors are differentially labeled by arylacetamides and benzomorphans. Eur J Pharmacol 485:119-25
Kuehne, Martin E; He, Liwen; Jokiel, Patrick A et al. (2003) Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem 46:2716-30
Zhou, Qun; Duan, Wen-hu; Cohen, Dana J et al. (2003) Synthesis and pharmacology of 8-amino-3-[(tetrahydro-2-furanyl)methyl] benzomorphan. Yao Xue Xue Bao 38:748-53
Wentland, Mark P; Ye, Yingchun; Cioffi, Christopher L et al. (2003) Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines. J Med Chem 46:838-49
Wentland, Mark P; Sun, Xufeng; Ye, Yingchun et al. (2003) Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 2: 8-formamidocyclazocine analogues. Bioorg Med Chem Lett 13:1911-4
Negus, S S; Bidlack, J M; Mello, N K et al. (2002) Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol 13:557-70
Bidlack, Jean M; Cohen, Dana J; McLaughlin, Jay P et al. (2002) 8-Carboxamidocyclazocine: a long-acting, novel benzomorphan. J Pharmacol Exp Ther 302:374-80
Parkhill, Amy L; Bidlack, Jean M (2002) Several delta-opioid receptor ligands display no subtype selectivity to the human delta-opioid receptor. Eur J Pharmacol 451:257-64
Wentland, M P; Lou, R; Ye, Y et al. (2001) 8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Bioorg Med Chem Lett 11:623-6
Wentland, M P; Lou, R; Dehnhardt, C M et al. (2001) 3-Carboxamido analogues of morphine and naltrexone. synthesis and opioid receptor binding properties. Bioorg Med Chem Lett 11:1717-21

Showing the most recent 10 out of 51 publications